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AbTPO  anti-thyroid peroxidase antibody 
AITD   autoimmune thyroid disorders 
ATC    anaplastic thyroid cancer 
CCL   chemokine (C-C motif) ligand 
CCR   chemokine (C-C motif) receptor 
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CTLA-4   Cytotoxic T-Lymphocyte Antigen4 
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PPCT   preprocalcitonin 
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TC   thyroid cancer 
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TKI   tyrosine kinase inhibitor 
TLR3   toll-like receptor 3 
TNF   tumor necrosis factor 
Treg   Regulatory CD4+ T cells 
TSH    thyroid stimulating hormone   
TSI   thyroid stimulating immunoglobulin 
UILN   uninvolved 
Abstract  
Introduction: Cancer immunotherapies were approved in recent years, including the immune 
checkpoint inhibitors. Experience with ipilimumab (CTLA-4 antagonist), nivolumab and 
pembrolizumab (PD-1 antagonists), and atezolizumab (PD-L1 antagonist) has shown that the impact 
on overall survival in cancer patients is paramount. Immune checkpoint inhibitors target the immune 
system, and they can be applied works across multiple cancers; the response rate is ranging from 20 
to 40%. Many studies have shown that thyroid cancer (TC) cells produce cytokines, and 
chemokines, inducing several tumor-promoting effects. Targeting and/or lowering cytokines, and 
chemokines concentrations within the tumor microenvironment would produce a therapeutic 
benefit. In TC, increased Treg and PD-1+ T cell frequencies are indicative of aggressive disease; and 
PD-L1 expression correlates with a greater risk of recurrence. 
Area covered: Searching in literature, few pioneering studies have evaluated immunotherapy in 
thyroid cancer. More recently it has been described one case of anaplastic thyroid cancer treated with 
vemurafenib and nivolumab, with substantial regression and complete radiographic and clinical 
remission.  
Expert Opinion/Commentary: The use of immune checkpoint inhibitors in aggressive TC has not yet 
been extensively investigated, and further studies in large number of TC patients, are urgently needed.   
1. Immunotherapy.      
Cancer immunotherapies were approved in recent years, including preventive and therapeutic cancer 
vaccines [1], the first “immune checkpoint inhibitors” [2-4], a bi-specific T-cell engager, and an 
oncolytic virus [5] (Table 1). Of these, immune checkpoint inhibitors that target the programmed 
death-1 (PD-1) pathway generated the most interest, with response rates across tumor types that 
average 20-30% [6]. A pressing challenge is transforming the majority of patients from immunotherapy 
non-responders to responders. This will likely require potent combination immunotherapies that 
effectively harness the cancer-immunity cycle [7].  
Cancer therapies result in tumor cell death and release of tumor antigens, which are presented by 
dendritic cells in the tumor-draining lymph nodes (LN) to prime and activate tumor immunity. Tumor-
specific T cells then gain access to the circulation and traffic to tumors, where they infiltrate the tumor 
mass. T cell-mediated lysis of cancer cells releases more tumor antigens, thus perpetuating the cycle. 
Multiple opportunities for therapeutic intervention that enhance tumor immunity are possible at each 
step of this cycle [7].  
The immune system has an important role in the recognition and eradication of tumor cells 
(“immune surveillance”). The knowledge of the relationships between the immune system and 
cancers leaded to the identification of key molecules that influence them. Cancer cells try to 
escape recognition and destruction by the immune system through multiple mechanisms. For 
example, tumor cells can dysregulate immune cell activity (of T cells and natural killer cells) 
activating T cell inhibitory pathways (checkpoint), as Cytotoxic T-Lymphocyte Antigen4 (CTLA-
4), Programmed Death-1 (PD-1), or suppression of NK cell activity, and others.  
CTLA-4 is a protein receptor that downregulates immune responses, functioning as an immune 
checkpoint. CTLA-4 is constitutively expressed in regulatory T cells, and upregulated in 
conventional T cells after activation. Binding to CD80 or CD86 on the surface of antigen-
presenting cells, it acts as an "off" switch. Anti-CTLA4 agents act in the priming phase of 
immune response through the inhibition of the interaction between CTLA-4 on T cell and B7 on 
antigen-presenting cell. The inhibition of negative regulation through binding of CTLA-4 has 
been shown to promote stimulation of adaptive immunity and potentiation of T cell activation. 
CTLA-4-blocking antibodies have shown to be efficient in various murine malignancy models 
upon administration as monotherapy.  
Ipilimumab, a fully human monoclonal antibody that blocks CTLA-4, was the first successfully 
developed drug belonging to a new class of therapeutics called “immune checkpoint inhibitors” 
[8]. 
Activated T-cells express also PD-1, another immune checkpoint target, that mediates 
immunosuppression. Its ligands PD-L1 (B7-H8) and PD-L2 (B7-DC) are expressed on many 
tumor and stroma cells and other cell types, as leucocytes. The immunosuppressive action of the 
PD-1 receptor is activated in the effector phase of the interaction between T lymphocytes and 
tumor cells. A new class of drugs that block PD-1, the PD-1 inhibitors, activate the immune 
system to attack different types of cancer with varying success [9].  
Experience with ipilimumab (a CTLA-4 antagonist), nivolumab and pembrolizumab (PD-1 
antagonists) and atezolizumab (a PD-L1 antagonist) in treating cancer has defined several key 
principles of cancer immunotherapy with immune checkpoint inhibitors. Immune checkpoint 
inhibitors target the immune system, engaging T cells with inherent capacity for adaptability and 
memory, underlining the durable responses and long-term survival observed with these agents, 
and they can be applied works across multiple cancers. Moreover, the side effects of immune 
checkpoint inhibitors are distinct from those of chemotherapy and targeted agents. Finally, the 
efficacy of immunotherapy can be improved by combining immune checkpoint inhibitors with 
other treatment strategies [10]. 
 1.1. Cancer immunotherapy with immune checkpoint inhibitors has unique patterns of clinical 
benefit 
The impact on overall survival (OS) of immune checkpoint inhibitors therapy is paramount. 
Ipilimumab prolongs OS with no impact on overall response rate (10%) or progression-free survival 
(PFS) in melanoma [2,11]. However the rate of PFS at week 12 was slightly higher in the 
ipilimumab-alone treated group [2]. There was a 24% reduction in the risk of progression in the 
ipilimumab–dacarbazine group as compared with the dacarbazin [11]. 
A recent phase III study making a comparison between nivolumab and everolimus in metastatic kidney 
cancer showed no difference in median PFS, but the median OS for patients treated with nivolumab 
was longer (25 versus 19.6 months) [10]. However the median PFS was slightly longer (4.6 months) 
in the nivolumab group than in the everolimus group (4.4 months) [12].  
This clinical benefit pattern may be related to the immune response evolution over time, or to pseudo-
progression, defined as an increase in size of the tumor mass on imaging from immune infiltration 
rather than tumor growth. A non-conventional response pattern led to the development of immune-
related response criteria, which preserve the potential of benefiting from immunotherapy despite 
apparent disease progression on imaging [13]. Thus, immunotherapy should be continued in the face of 
apparent disease progression by imaging if the patient is doing well, and/or until progressive disease is 
confirmed by a second scan 4 weeks later. 
A meta-analysis of 5000 patients with advanced melanoma reported that ipilimumab rendered 
melanoma a chronic disease in 20% of patients [14]. Early data with single-agent nivolumab [4,15,16], 
pembrolizumab [17], and combination of ipilimumab/nivolumab [18,19] suggest that PD-1 antagonists 
could result in even more long-term responders. Relative to CTLA-4 blockade, PD-1/PD-L1 blockade 
appears to double the number of long-term responders. PD-1 blockade also appears to give higher 
objective response rate (ORR)s and longer PFS than CTLA-4 blockade [20,21]. The effectiveness of 
the combination of CTLA-4 and PD-1/PD-L1 blockade is even higher, and it is likely that OS will 
continue to improve with effective combination immunotherapies.  
PD-L1 overexpression predicts activity as well as better survival for patients treated with 
immune checkpoint inhibitors [22].  
 
1.2. Immunotherapy with immune checkpoint inhibitors targets a broad range of tumor types  
Because cancer immunotherapy targets the immune system, it can be effective independently from 
tumor stage or driver mutations, as ipilimumab has long-term benefit for cutaneous, ocular and 
mucosal melanomas, which have distinct biology [23-28]. There was no difference between BRAF- 
and NRAS-mutated melanoma in duration of response or OS with ipilimumab [29]. Moreover, the 
efficacy of PD-1 blockade extends to multiple tumor types, including kidney cancer, small-cell lung 
cancer (SCLC), non-small-cell lung cancer (NSCLC), Hodgkin’s lymphoma, head and neck cancer, 
esophageal and gastric cancers, hepatocellular cancer, bladder cancer, breast cancer and others [6,30]. 
However PD-1 blockade often is more effective in certain subtypes of cancer. For example 
clinical activity appears more likely in triple negative PD-L1+ breast cancer [31]. Thus, it is 
possible to achieve long-term survival in some patients across a range of distinct tumor types, where 
the different response rates across tumors reflect different immunogenicity. 
 
1.3. Spectrum of toxicities 
Nearly, every organ can be affected with immune-related adverse effects. Published clinical trial data 
suggest that overall 7–19% of patients receiving anti-PD1/PD-L1 antibodies experienced grade 3–5 
adverse events [12,20,32-36]. The discontinuation rate of immune checkpoint inhibitors due to adverse 
events ranged from 3% to 8% for anti-PD-1/PD-L1 antibodies [12,17,20,21,32-34], and up to 15% for 
ipilimumab [20,21]. The discontinuation rate due to adverse effects with the combination treatment of 
nivolumab, plus ipilimumab, is significantly higher, at a rate of 36% [20]. Time to onset of immune-
related adverse events, however, is variable [37]. The addition of immune checkpoint inhibitors with 
chemotherapy does not accentuate the cytotoxic toxicities of chemotherapy, but does add the additional 
risk of immune-related toxicities [38]. 
 
1.4. Immune-related endocrine toxicities  
Immune-related endocrine toxicities include hypophysitis, thyroid dysfunction, adrenal insufficiency 
and type 1 diabetes mellitus. Immune-related endocrine toxicities are one of the few toxicities which 
are commonly irreversible, with studies showing recovery of the pituitary–thyroid axis in up to 50% of 
patients [39] and in 50–60% for the pituitary–gonadal axis [39-41]. Very few cases of corticotroph 
recovery have been reported [40].  
About the onset time of immune-related adverse events, hypophysitis was reported in patients in 
the initial pembrolizumab clinical trial database with a time to onset as far as 1.7 months, 
similarly to the onset of hypophysitis described in ipilimumab clinical trials. In a phase III 
nivolumab trial conducted in advanced melanoma patients, thyroid dysfunctions occurred with a 
time to onset ranging from 24 days to 11.7 months from the beginning of the therapy [42].  
 
1.5. Thyroid disorders induced by immunotherapy 
Thyroid abnormalities are the second most common endocrine-related immune adverse effect 
secondary to anti-CTLA-4-antibodies [39] and can occur in 1–6% of patients treated with immune 
checkpoint inhibitors [40,41]. The incidence is closer to 10% in patients treated with single agent anti-
PD-1/PD-L1 [20,21]. It may present as thyrotoxicosis, hypothyroidism, painless thyroiditis, or more 
severe disorders such as “thyroid storm” [40]. Most cases of anti-CTLA-4 thyroiditis are subclinical 
and occur after 2–4 infusions [39]. Also other less frequent endocrine disorders have been reported 
such as euthyroid Graves’ ophthalmopathy [43,44].  
 
1.6. Mechanisms leading to thyroid disorders 
Thyroid disorders induced by immunotherapy are due to an autoimmune reaction against thyroid 
leading to a destructive thyroiditis with release of thyroid antigen and then antibody production. The 
beginning hyperthyroid phase is characterized by high thyroglobulin (Tg) levels in most of the patients 
(without anti-Tg as well as elevated anti-Tg and thyroid stimulating immunoglobulin (TSI), in 40 and 
50% of the subjects, respectively) with evidence of thyroiditis in patients with available imaging. In the 
major part of these patients, normalization of Tg is in favour of a destructive process leading to 
permanent hypothyroidism [41,45-50].  
In patients with high TSI levels, it is not probable that this can lead to thyrotoxicosis as available 
imaging in patients were less indicative of Graves’ (an ultrasonographic hypoechoic pattern of the 
thyroid). 
Cancer patients treated with anti-CTLA-4 or anti-PD-1, with previous diagnosed autoimmune thyroid 
disorders (AITD), or circulating antithyroglobulin antibodies (AbTg), antithyroperoxidase antibodies 
(AbTPO), more frequently develop a thyroid dysfunction or a destructive thyroiditis [45-50] (in about 
80% of cases). However thyroid dysfunctions may occur also in patients without circulating 
thyroid autoantibody [51].  
Interestingly, an elevated antitumor response was present in some series of patients with circulating 
anti-thyroid autoantibodies, suggesting an association between inflammatory and tumor response [45]. 
Moreover, the appearance of AbTg was associated with prolonged survival [52]. 
 
1.7. Management of thyroid disorders 
Thyroid function tests are to be checked at baseline and then every 2 months while on treatment with 
immune checkpoint inhibitors [53]. Immune checkpoint therapy can be continued for grade 1–2 
hyperthyroidism, and treatment is initiated for symptoms of hyperthyroidism [54,55]. In case of 
symptomatic hyperthyroidism (grade 3), immune checkpoint inhibitor therapy should be withheld and 
corticosteroids commenced (oral prednisolone 1–2 mg/kg/day) [54]. If necessary antithyroid 
medications (methimazole, propilthyouracil, or carbimazole) may be indicated. In case of severe 
hyperthyroidism (grade 4), immune check-point inhibitor therapy should be permanently stopped, and 
methylprednisone (1–2 mg/kg/day; IV) should be administered for 3 days, followed by oral 
prednisolone (1–2 mg/kg/day), which is tapered over at least 1 month [54].  
To distinguish the pathogenesis of hyperthyroidism, thyroid ultrasound and the study of thyroid 
vascularization could be useful, in fact hyper-vascularity is associated with Graves’ disease, while 
hypo-vascularity is associated with destructive thyroiditis.  
Primary hypothyroidism is diagnosed if thyroid stimulating hormone (TSH) levels are increased 
in presence of a low free thyroxine (T4) level, whereas hypophysitis is characterized by a low 
TSH and low free T4. In case of primary hypothyroidism immune checkpoint inhibitor therapy 
can be continued with appropriate levothyroxine replacement [42]. Hypophysitis can present as 
fatigue, headaches, and visual field defects. Diagnosis is established according to levels of 
pituitary hormones (ACTH, TSH, FSH, LH, GH, IGF-1 and prolactin) and nuclear magnetic 
resonance (NMR) imaging showing an enlarged pituitary, with/without necrosis. For grade ≥2 
toxicity it is adviced to withhold immune checkpoint inhibitor therapy and start high-dose 
corticosteroids (methylprednisolone 125 mg daily intravenously for 3 days with a switch to oral 
prednisone 1-2 mg/kg daily upon improvement of symptoms). The corticosteroid therapy (which 
is quite frequent in neoplastic subjects) may have a direct effect on the pituitary by reducing 
TSH levels. Furthermore corticosteroid therapy can be associated with an “euthyroid sick 
syndrome” (also known as nonthyroidal illness syndrome) characterized by low serum 
triiodothyronine (T3) and elevated reverse T3 (rT3). This might affect differential diagnosis 
when evaluating thyroid function tests [42]. 
Regular monitoring of thyroid function tests during the treatment period should allow for early 
detection of hypothyroidism, prior to the patient becoming symptomatic. If the patient is symptomatic, 
the clinical situation should be evaluated on an individual basis to evaluate whether the immune 
checkpoint inhibitor should be withheld [40,54,56].  
 
2. Aggressive thyroid cancer. 
More than 90% of thyroid cancer (TC) are differentiated thyroid carcinomas arising from follicular 
cells (DTC)  [papillary thyroid cancer (PTC) 90%, follicular thyroid cancer (FTC) 10%], 5% are 
medullary thyroid cancer (MTC), and <5% are anaplastic thyroid cancer (ATC), or other rare 
histological types.  
Thyroid cancer derived from follicular epithelium. 
PTC and FTC patients are usually treated with total thyroidectomy, and radioiodine is performed in 
patients with an elevated risk, and evaluated in DTC patients with an intermediate risk. Throughout 
tumor progression, DTC cells can lose the iodide uptake ability, and become resistant to radioiodine;  
this worsens the prognosis, and DTC becomes “aggressive dedifferentiated TC” (PDTC).  
Thyroid surgery has minimal effect in ATC, and the other therapies are not beneficial [57,58]. Further 
attempts in the development of new drugs are going on owing to the absence of specific and effective 
drugs for the treatment of PDTC.  
Thyroid cancer derived from C-cells. 
Surgery is the only curative treatment of MTC; however, no definitive treatment is possible for 
recurrent or metastatic MTC. 
Molecular pathways alterations in thyroid cancer and targeted therapies. 
In the last years, different genetic alterations in the molecular pathways, determinant for the 
development and progression of TC, have been identified (BRAF mutations, TERT promoter 
mutations, RAS mutations, RET/PTC gene rearrangements, RET mutations). Tyrosine kinase 
inhibitors (TKIs) are small organic compounds able to inhibit tyrosine kinases auto-phosphorylation 
and activation. Most of them are multi-kinase inhibitors acting on the above reported molecular 
pathways, and consequently in growth, angiogenesis, and local and distant spread of TC and for this 
reason are now considered as new therapies of aggressive TC, as they can induce clinical responses and 
stabilization of the disease [57,58]. Median PFS is improved by these drugs, but no significant OS 
increase has been shown until now; side effects are common, and they may be severe.  
New attempts are needed to find novel, more effective and safe therapies in patients with PDTC. 
Moreover, immunotherapy in PDTC has not yet been extensively evaluated. 
 
3. Immune response in TC. 
Many studies have evaluated the immune response, and the involvement of cytokines and chemokines, 
or immune competent cells in human TC.  
3.1 Evaluation of the immune response in human TC: cytokines and chemokines 
In the last few years, experimental evidence has accumulated showing that chemokine (C-X-C motif) 
receptor (CXCR)3, and its ligands [the interferon (IFN)-γ inducible chemokine (C-X-C motif) ligand 
(CXCL)9, CXCL10, CXCL11] play an important role in the immune pathogenesis of autoimmune 
disorders involving thyroid and endocrine glands [59,60]. In fact, after IFN-γ stimulation, thyroid 
epithelial cells secrete CXCL10, which induces the chemotaxis of type-1 T-helper lymphocytes, that 
further secrete IFN-γ, thus initiating and perpetuating the autoimmune process. In PTC, RET/PTC 
rearrangements, and BRAF or RAS activating mutations lead to the up-regulation of CXCL10, 
stimulating proliferation and invasion [61,62]. Furthermore, elevated basal levels of Toll-like receptor 
3 (TLR3) and non-canonical WNT5a RNA have been reported in PTC cell lines. TLR3 are functional 
in PTC cells, leading to increase significantly CXCL10 levels, the TLR3 signaling end product [63]. In 
primary cultures of PTC cells, IFN-γ induced a CXCL10 release more than ten times higher than in 
normal follicular thyroid cells. Furthermore a deregulation of CXCL10 secretion was observed, in fact 
PPAR-gamma agonists inhibited CXCL10 secretion in normal thyroid follicular cells, and stimulated it 
in PTCs [64].  
Also ATC cells produce CXCL10, basally and under the influence of cytokines. However, the pattern 
of modulation by IFN-γ, tumor necrosis factor (TNF)-α or thiazolidinediones strongly varies, 
suggesting that the intracellular pathways involved in the chemokine modulation in ATC have different 
types of deregulation [65]. ATC cell lines are sensitive to lysis by ex vivo expanded natural killer (NK) 
cells, and the lysis was abrogated upon blockade of NKG2D [66]. Moreover, ATC cell lines produced 
high levels of CXCL10 and stimulated migration of expanded NK cells, and ATC tumors were 
enriched for NK cells expressing the cognate chemokine receptor CXCR3 [66].  
In different human carcinoma types, mast cell infiltrate increases in the tumoral tissue and mast cell 
density correlates with a bad prognosis. A recent study suggested that mast cells are recruited into 
thyroid cancer, promoting proliferation, survival and invasive ability of cancer cells, in this way 
contributing to thyroid cancer growth and invasiveness, principally mediated by histamine, CXCL1 and 
CXCL10 (mast-cell-derived mediators) [67]. 
A study assessed the expression of the chemokine receptors chemokine (C-C motif) receptor (CCR)3, 
CCR7, and CXCR4 in tumor and nonmalignant thyroid tissues from patients with PTC. Expression of 
these receptors in PTC was correlated with the clinical pathological condition of PTC. The results 
suggested that CCR3, CCR7, and CXCR4 are increasingly expressed in tumor cells from more 
aggressive PTC, being CXCR4 expression a potential marker for enhanced tumor aggressiveness [68].  
The importance of mast cells derived mediators (as the chemokines CXCL1, CXCL10, and CXCL8) in 
the context of TC has been demonstrated. CXCL1 and CXCL10 contribute to the stimulation of cell 
proliferation, while CXCL8 is involved in the acquisition of TC malignant traits inducing or enhancing 
the epithelial mesenchymal transition and stem-like features of TC cells [69].  
CXCL8 displays several tumor-promoting effects. Targeting and/or lowering CXCL8 concentrations 
within the tumor microenvironment would produce a therapeutic benefit. It was demonstrated that IFN-
γ inhibits CXCL8 secretion and in turn the migration of a BRAFV600E mutated thyroid cell line [70].  
Furthermore, primary ATC cells produce chemokine (C-C motif) ligand (CCL)2 basally and after 
cytokines stimulation, with an extremely variable pattern of modulation, suggesting different types of 
deregulation in the chemokine modulation. Serum CCL2 is increased in ATC patients. Further studies 
will be necessary to evaluate if CCL2 might be used as a marker in the follow-up of ATC patients [71]. 
The inhibition of chemokine signaling could be considered as a novel therapeutic approache for the 
treatment of refractory forms of TC.  
 
3.2 Evaluation of the immune response in human TC: PD-1+ T cell, PD-L1, Treg, cytotoxic T cells 
and NK cells  
To characterize the immune response to metastatic PTC, CD4+ T cell polarization was assessed, such 
as the role of PD-1 and T cell exhaustion. T cell subset frequencies were compared in Uninvolved 
(UILN) and tumor-involved lymph nodes (TILN) and assessed for correlation with recurrent disease 
and extranodal invasion. Regulatory CD4+ T cells (Treg) were enriched in TILN compared with UILN 
and further elevated in TILN from patients with recurrent disease. PD-1+ T cells were present at high 
frequency in TILN and markedly enriched in TILN that showed evidence of extranodal invasion. In 
TILN, Treg frequency correlated with PD-1+ T cell frequencies. The Authors suggested that increased 
Treg and PD-1+ T cell frequencies in LN may be indicative of aggressive recurrent PTC [72].  
In another study BRAFV600E mutated patients samples showed higher PD-L1 mRNA levels with respect 
to BRAFWT TC patients [73].  
A study evaluated PD-L1 expression in PTC and its variants, to determine its prognostic value to 
predict clinical outcome in these patients. PD-L1 immunostaining was principally localized in 
cytoplasm and occasionally in plasma tumor cell membranes. Patients with increased PD-L1 membrane 
or cytoplasmic positivity had significantly shorter median disease free survival (36 months, and 49 
months, respectively) with respect to those with PD-L1 negative tumors (both 186 months). 
Considering PD-L1+ and PD-L1- patients and PTC staging, an increased cytoplasmic positivity was 
present in all four stages of PTC showing a greater risk of recurrence and a poor prognosis. These data 
suggest PD-L1 positive expression in PTC correlates with a greater risk of recurrence and shortened 
disease free survival leading to hypothesize that it could be considered as a prognostic marker for PTC 
[74].  
However, it may be possible that PD-L1 expression in TC simply correlates with a yet undefined 
and more aggressive subtype of TC. 
Other studies support the presence of an antitumor immune response in advanced TCs linked to 
cytotoxic T cells (CTL) and NK cells. This antitumor response is likely blunted by the presence of 
immunosuppressive pathways within the microenvironment, facilitated by tumor-associated 
macrophages or increased expression of negative regulators of CTL function [75]. 
Recently it has been shown that PD-L1 was positively expressed in 53.2% of PTCs [76], while a 
very low expression of PD-L1 in MTC was observed [77].  
 
4. Immunotherapy in TC. 
4.1 Experimental models of immunotherapy in TC 
Along the lines of other studies that performed a preclinical evaluation of immunotherapy in other 
kinds of cancer (for example colon cancer, melanoma, etc.) [78-80], the effect of immune checkpoint 
inhibitors has been evaluated in syngenic immune-competent models of TC in mice [78-80].  
In an immuno competent orthotopic mouse model of ATC, combined PLX4720 and dasatinib treatment 
exerted a significant antineoplastic response, and immune cell infiltration was increased by PLX4720 
treatment [81].  
In another paper, BRAFV600E cells showed significantly higher baseline expression of PD-L1 at mRNA 
and protein levels versus BRAFWT cells. Treating all cell lines with MEK inhibitor, PD-L1 expression 
decreased. BRAF inhibitor treatment decreased PD-L1 expression in BRAFV600E cells, but increased it 
in BRAFWT cells. Immunocompetent mice (B6129SF1/J) implanted with syngenic 3747 BRAFV600E/WT 
P53-/- murine tumor cells were randomized to control, PLX4720, anti PD-L1 antibody and their 
combination. The combination dramatically reduced tumor volume, compared to PLX4720 or PD-L1 
antibody alone. Immunohistochemistry analysis revealed intense CD8+ CTL infiltration and 
cytotoxicity and favorable CD8+: Treg ratio compared to each individual treatment. These results 
suggested anti PD-L1 treatment potentiates the effect of BRAF inhibitor on tumor regression and 
intensifies anti tumor immune response in an immune-competent model of ATC [73].  
NY-ESO-1 is one of the most immunogenic members of the cancer/testis antigen family, and 
demethylating and deacetylating agents can increase its levels. This cytoplasmic antigen is considered  
a potent target for cancer immunotherapy. A study evaluated the baseline expression of NY-ESO-1 
messenger RNA and protein before and after exposure to 5-aza-2'-deoxycytidine (DAC) (72 hours) in 
different TC cell lines. None of the TC cell lines showed baseline expression of NY-ESO-1. However, 
the NY-ESO-1 gene expression increased in BCPAP, TPC-1, and 8505c cell lines after DAC treatment. 
Furthermore, in vivo DAC treatment increased NY-ESO-1 expression in an orthotopic mouse model 
with BCPAP cells, suggesting that many differentiated TC cells can be pressed to express immune 
antigens, that successively can be utilized in TCR-based immunotherapeutic interventions [82]. 
A recent study evaluated the effects of NK cell-based immunotherapy for pulmonary metastasis of 
ATC. Human NK cells (NK-92MI) were retrovirally transduced to express the effluc gene. Human 
ATC cells (CAL-62) were transduced with the effluc and Rluc genes. To evaluate the targetability of 
NK cells to ATC tumors, NK-92MI cells expressing the effluc gene (NK/F) were administered through 
the tail vein of nude mice with a pulmonary metastasis or tumor xenograft. An ATC pulmonary 
metastasis mouse model was generated, and NK cells significantly inhibited the growth of the 
metastasis. These results suggest that NK cells are able to target ATC tumors and that NK cell-based 
immunotherapy may be effective for pulmonary metastases of ATC [83]. 
No effective therapies are known for patients suffering from progressive MTC, a calcitonin (CT)-
secreting C cell tumor. As CT, which arises from the precursor protein preprocalcitonin (PPCT), is 
expressed by almost all MTCs, these molecules may represent target antigens for immunotherapy 
against MTC. A study investigated whether DNA immunization induced cellular and humoral immune 
responses against human PPCT (hPPCT) in mice. The results showed that cellular and humoral 
immune responses against hPPCT can be generated by DNA immunization and increased by 
coinjection of the GM-CSF gene, suggesting the use of DNA immunization as a potential novel 
immunotherapeutic therapy for MTC patients [84].  
 
4.2 Immunotherapy of TC in humans 
In a pioneering study human Tg (altered with the diazonium derivatives of arsanilic and sulfanilic 
acids, and with Freund adjuvant) was used to induce autoimmune thyroiditis in humans with 
untreatable metastatic TC. There was minimal toxicity during the therapy, and it was possible to create 
autoimmune thyroiditis in 3/8 patients. Antibodies to Tg were induced in 5/8 patients (62.5%). 
However, the clinical response to the immunotherapy was minimal [85]. 
Recently some studies investigated the role of dendritic cells (DCs) within the immune system and how 
to generate and activate these cells to induce cytotoxic immunity in tumors. DC vaccinations in patients 
with endocrine malignancies (mainly in metastasized MTC) resulted in tumor-specific immunity and 
partial clinical responses in some cases. For these reasons, new DC vaccination protocols for the 
treatment of patients with endocrine tumors have now been conducted [86]. 
Furthermore it was shown that oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-
1/CCL2 expression and impairs angiogenesis and macrophage infiltration in ATC [87]. 
More recently it has been described a 52-year-old male who was diagnosed with ATC and initially 
treated with a thyroidectomy and LN dissection, followed by chemotherapy. Next generation 
sequencing was then performed to guide therapy and the tumor was found to have BRAF and PD-L1 
positivity, and it was subsequently treated with vemurafenib and nivolumab. This led to substantial 
regression of ATC, and in complete radiographic and clinical remission 20 months after the beginning 
of the treatment with nivolumab [88]. 
 
Conclusion.  
In aggressive TC, TKI therapy prolongs median PFS, but until now no significant increase has been 
observed on OS; side effects are common, and severe [57,89-91]. New efforts are needed to obtain new 
effective and safe therapies for PDTC patients.  
Many studies have shown that TC cells produce cytokines, and chemokines, that induce several tumor-
promoting effects. Targeting and/or lowering cytokines, and chemokines concentrations within the 
tumor microenvironment would produce a therapeutic benefit.  
Increased Treg and PD-1+ T cell frequencies are indicative of aggressive, recurrent PTC. PD-L1 
positive expression in PTC correlates with a greater risk of recurrence and shortened disease free 
survival. Moreover, other studies support the presence of an anti-tumor immune response in advanced 
thyroid cancers linked to CTL and NK cells, that is blunted by the presence of immunosuppressive 
pathways within the microenvironment, facilitated by tumor-associated macrophages or increased 
expression of negative regulators of CTL function [72-75].  
Few pioneering studies have evaluated immunotherapy in TC [85,86]. More recently it has been 
described one case of ATC treated with vemurafenib and nivolumab, with substantial regression and in 
complete radiographic and clinical remission 20 months after the beginning of the treatment with 
nivolumab [88].  
The use of immune checkpoint inhibitors in aggressive TC has not yet been extensively investigated, 
and further studies in large number of TC patients, are urgently needed.  
 
Expert commentary. 
The use of immune checkpoint inhibitors in aggressive TC has not yet been investigated and further 
studies are urgently needed. Since it has been shown that PD-L1 was positively expressed in 53.2%  
of PTCs [76], and since PD-L1 positive patients had a significantly higher response rate than PD-
L1 negative [92], it is reasonable to expect an overall 20-40% response rate in TC patients by immune 
checkpoint inhibitors, such as in other types of cancer.  
A pressing challenge is transforming the majority of cancer patients from immunotherapy non-
responders to responders. TC has some peculiarities that will be used to increase the responder rate.  In 
fact, about 20% of TC patients are also affected by AITD. Patients treated with anti-CTLA-4 or anti-
PD-1, with previous diagnosed AITD, or circulating AbTg, or AbTPO, more frequently develop a 
thyroid dysfunction or a thyroiditis [45-50], strongly suggesting that immunotherapy stimulates the 
immune process associated with AITD in these patients. In the major part of these cancer patients, 
thyroid dysfunctions by checkpoint inhibitors lead to a destructive thyroiditis leading to permanent 
hypothyroidism. The induction of a destructive thyroiditis could be theoretically beneficial in patients 
with TC and residual thyroid tissue, because it could lead to a partial destruction of the TC tissue itself; 
this point needs to be investigated.  
However, the prevalence of the appearance of a thyroid disorder in patients treated with 
immunotherapy is low (5-10%). In consideration that with immune checkpoint inhibitors therapy the 
appearance of a destructive thyroiditis is observed in up to 80% of cancer patients, with AITD [45-50], 
it could be hypothesized a higher response rate in TC patients with AITD, and a more potent 
antineoplastic effect in these patients, opening the way to a selective use of immune checkpoint 
inhibitors in TC patients with AITD.  
It is also necessary to consider that a destructive thyroiditis leading to destruction of the tumoral TC 
tissue will not result in a thyroid dysfunction, since TC patients have been previously submitted to total 
thyroidectomy, and euthyroidism is maintained with L-T4 therapy. 
The stronger antineoplastic immune response observed in cancer patients treated with immune 
checkpoint inhibitors in presence of AITD [45], and the observation that the appearance of AbTg was 
associated with prolonged survival [52], suggest that also cancer patients (not TC) with AITD are more 
likely to be treated with immune checkpoint inhibitors. 
Furthermore in TC patients without AITD, it could be speculated that the induction of an 
autoimmune process against a specific antigen present in the tumor itself could evoke a stronger 
immune response specifically directed against the antigen itself. With this view, it has to be noticed that 
thyroid has antigens uniquely expressed by the thyroid tissue itself. For example, Tg is an antigen 
expressed specifically and uniquely by the thyroid tissue. In fact, Tg is very useful as tumoral marker in 
patients with PTC, FTC, or PDTC, after thyroidectomy and radioiodine ablation, since the presence of 
circulating Tg is a specific indicator of the presence of residual thyroid tissue. This generates the 
opportunity to evaluate in aggressive PTC, or FTC, or PDTC if immunotherapy could be specifically 
directed and enhanced against the thyroid tissue by pre-induction of an autoimmune reaction against a 
specific antigen of the tissue itself, that in this case is Tg. Considering that the responder rate with 
immune checkpoint inhibitors is ranging from 20 to 40% (in other cancers) [7,21,57,89-91,93], and 
since the appearance of a destructive thyroiditis is observed in up to 80% of cancer patients with 
circulating AbTg (after immune checkpoint inhibitors therapy) [45-50], it is possible to hypothesize 
that a specific immunization with Tg, in PDTC patients (initially without AITD), will lead to the 
appearance of AbTg in about 60% of them [85], increasing the number of responders  to immune 
checkpoint inhibitors. Furthermore, an elevated antineoplastic response was observed in cancer patients 
treated with immune checkpoint inhibitors in presence of AITD [45], and the appearance of AbTg was 
associated with prolonged survival [52]. So it is possible to hypothesize that the combination of the 
induction of an autoimmune reaction against Tg, and immune checkpoint inhibitors, will induce in 
PDTC a more potent antineoplastic effect (than immune checkpoint inhibitors alone), and a prolonged 
survival. 
Since the presence of AbTg was associated with a more potent antineoplastic effect of immune 
checkpoint inhibitors, and prolonged survival [45,52], it will be possible to hypothesize that the 
combination of the induction of an autoimmune reaction against Tg, and immune checkpoint inhibitors 
therapy, will be used also in other cancers to induce the appearance of AbTg, increasing the responder 
rate, and the antineoplastic response. 
Theoretically, in case that a cancer antigen specific immunization might induce a stronger and 
specifically directed immune response (against the cancer that contains the above mentioned antigen), 
the induction of an autoimmune reaction could be used also in other cancers that contain specific 
antigens, or that overexpress an antigen (for example, CT, or PPCT [84] in MTC, or CEA in colon 
cancer, etc.), in association with immune checkpoint inhibitors therapy.  
 
 
Five-year view. 
 Immune checkpoint inhibitors will be used in different types of aggressive TC in humans 
(PDTC, MTC, ATC); it is reasonable to expect an overall 20-40% response rate in TC-P by immune 
checkpoint inhibitors. Probably, the effectiveness of the combination of CTLA-4 and PD-1/PD-L1 
blockade on OS will be proved to be higher, than single therapy (such as in other cancers). 
A pressing challenge is transforming the majority of cancer patients from immunotherapy non-
responders to responders. Since about 20% of TC-P are also affected by AITD, and since the 
appearance of a destructive thyroiditis is observed in up to 80% of cancer patients with AITD (leading 
to destruction of the TC tissue) [45-50], it will be investigated if AITD lead to a higher response rate by 
immune checkpoint inhibitors in TC patients with AITD, and to a more potent antineoplastic effect; 
opening the way to a selective use of immune checkpoint inhibitors in TC patients with AITD.  
The stronger antineoplastic immune response observed in cancer patients treated with immune 
checkpoint inhibitors in presence of AITD [45], and the observation that the appearance of AbTg was 
associated with prolonged survival [52], could be investigated to evaluate if also other cancer patients 
(not TC) with AITD are more likely to be treated with immune checkpoint inhibitors. 
Furthermore in TC patients without AITD, the combination of the induction of an autoimmune 
reaction against Tg, and immune checkpoint inhibitors therapy, could be evaluated to induce a higher 
response rate, and a more potent antineoplastic effect (than immune checkpoint inhibitors alone). 
Since the presence of AbTg was associated with a more potent antineoplastic effect of immune 
checkpoint inhibitors, and prolonged survival [45,52], the combination of the induction of an 
autoimmune reaction against Tg, and immune checkpoint inhibitors, could be investigated also in other 
types of cancer, to induce the appearance of AbTg, increasing the responder rate, and the antineoplastic 
response. 
The induction of an autoimmune reaction will be investigated also in other cancers that contain 
specific antigens, or that overexpress an antigen (for example, CT, or PPCT in MTC, or CEA in colon 
cancer, etc.), in association with immune checkpoint inhibitors therapy.  
 
 Key issues. 
• Cancer immunotherapies were approved in recent years, including the immune checkpoint 
inhibitors: ipilimumab (a CTLA-4 antagonist), nivolumab and pembrolizumab (PD-1 
antagonists), and atezolizumab (a PD-L1 antagonist). 
• Immune checkpoint inhibitors engage T lymphocytes (Treg and PD-1+ T-cells) with inherent 
capacity for adaptability and memory. This mechanism of action underlies the durable responses 
and long-term survival observed with these agents.  
• Immune checkpoint inhibitors target the immune system, and can work regardless of either 
cancer histology, or the presence of driver mutations. 
• The impact on “overall survival” of immune checkpoint inhibitors is paramount. Ipilimumab 
rendered melanoma a chronic disease in 20% of patients. Immune checkpoint inhibitors that 
target the PD-1 pathway show response rates, across tumor types, that average 20-30%. 
Combining CTLA-4 and PD-1/PD-L1 blockade is even more effective, with response rate 
ranging 20-40%.  
• A pressing challenge is transforming the majority of cancer patients from immunotherapy non-
responders to responders, with potent combination of immunotherapies. 
• Many studies have shown that TC cells produce cytokines, and chemokines, that induce several 
tumor-promoting effects. Targeting and/or lowering cytokines, and chemokines concentrations 
within the tumor microenvironment would produce a therapeutic benefit.  
• Increased Treg and PD-1+ T cell frequencies in TC are indicative of aggressive, recurrent TC. 
PD-L1 positive expression in PTC correlates with a greater risk of recurrence and shortened 
disease free survival. Moreover, other studies support the presence of an antitumor immune 
response in advanced TC linked to CTL and NK cells, that is blunted by the presence of 
immunosuppressive pathways within the microenvironment. 
• Few pioneering studies have evaluated immunotherapy in TC in humans.  
• More recently it has been described one case of ATC treated with vemurafenib and nivolumab, 
with substantial regression and complete radiographic and clinical remission. 
• The use of immune checkpoint inhibitors in aggressive TC has not yet been extensively 
investigated, and further studies in large number of TC patients, are urgently needed.   
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Table 1. Main experimental or approved immunotherapies in  human cancer. 
 
Main 
drugs 
Cancer 
types 
Basic 
mechanis
m  
Main 
reported 
effects 
Major 
disadvantages 
Approved 
Immunotherapi
es 
Referen
ce 
Immune 
checkpoint 
blockade 
 
anti-CTLA-
4 
(ipilimumab
) 
 
 
 
 
 
 
 
 
 
 
anti-PD-1 
and anti-
PD-L1 
(nivolumab) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
melanoma 
(ocular and 
mucosal 
melanoma
s) 
 
 
 
 
 
 
 
 
NSCLC, 
SCLC, 
kidney 
cancer, 
Hodgkin’s 
lymphoma, 
head and 
neck 
cancer, 
esophagea
l and 
gastric 
cancers, 
hepatocellu
lar cancer, 
bladder 
cancer, 
breast 
cancer 
 
 
 
 
 
- Activates 
pre-existing 
anticancer T 
cell 
responses, 
by blocking 
CTLA-4 
function, and 
possibly 
triggering 
new ones  
 
 
-It prevents 
the binding 
between PD-
1 and its 
ligands PD-
L1 and PD-
L2  
 
 
 
 
-Prolongs OS 
with no impact 
on overall 
response rate 
or PFS  
 
 
 
 
 
 
 
-It is possible 
to achieve 
long-term 
survival in 
some patients 
across a range 
of distinct 
tumor types, 
where the 
different 
response rates 
across tumors 
reflect different 
immunogenicit
y 
 
 
 
 
-A clinical benefit 
has been reached 
by only few 
patients 
-About 35 % of 
patients showed 
severe immune-
related adverse 
events 
 
 
 
 
-A clinical benefit 
has been reached 
by only few 
patients 
 
 
 
 
 
-For unresectable 
or metastatic 
melanoma 
 
 
 
 
 
 
 
 
 
-For the treatment 
of advanced 
melanoma, 
advanced 
NSCLC, 
advanced renal 
cell carcinoma, 
classical Hodgkin 
lymphoma, 
advanced 
squamous cell 
carcinoma of the 
head and neck, 
urothelial 
carcinoma, MSI-H 
or dMMR 
metastatic 
colorectal cancer, 
and hepatocellular 
carcinoma 
 
 
 
 
2, 11, 23-
28 
 
 
 
 
 
 
 
 
 
 
6, 10, 12, 
30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibition 
of 
chemokin
e signaling 
 
 
 
 
 
 
 
 
IL-2 
 
Many types 
of cancers, 
such as 
thyroid 
cancer;  
metastatic 
renal cell  
Carcinoma; 
metastatic 
melanoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
-Host’s 
-May offer 
novel 
therapeutic 
approaches for 
the treatment 
of refractory 
forms of 
cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-A low rate of 
 
 
 
 
 
 
 
 
 
 
 
 
 
-  Proleukin® 
70, 71 
 
 
 
 
 
 
 
IFN-α 
immune 
system 
stimulation 
 
 
 
 
 
-Host’s 
immune 
system 
stimulation 
 
 
 
 
 
 
 
 
response and a 
significative risk  
of systemic 
Inflammation 
 
 
 
 
-A low rate of 
response and  
toxicity at high-
dose  
 (aldesleukin) is 
approved for the 
treatment of  
metastatic renal 
cell  
carcinoma and 
metastatic 
melanoma 
 
- INTRON 
® A   (Interferon   
alfa-2b is 
approved  for the 
treatment of  hairy 
cell leukemia, 
malignant 
melanoma, AIDS-
related Kaposi's 
sarcoma, follicular 
non-Hodgkin's 
lymphoma, and 
condyloma 
acuminata 
   
Cell-based 
therapies 
 
DCs 
vaccination
s  
 
 
 
 
 
 
 
 
 
 
 
oncolytic 
virus dl922-
947 
 
 
 
endocrine 
malignanci
es (mainly 
in 
metastasiz
ed MTC) 
 
 
 
 
 
 
 
 
ATC and 
melanoma 
 
 
 
-
Immunization 
by antigen-
loaded DCs 
 
 
 
 
 
 
 
 
 
 
- Acts killing 
tumor cells 
and also  
inducing a 
long-lasting 
CD8 
T cell-
mediated anti-
tumor 
response 
 
 
 
 
 
-Resulted in 
tumor-specific 
immunity  
 
 
 
 
 
 
 
 
 
 
-Reduces IL-
8/CXCL8 and 
MCP-1/CCL2 
expression 
and impairs 
angiogenesis 
and 
macrophage 
infiltration 
 
 
 
-Partial clinical 
responses in 
some cases 
 
 
 
 
 
 
 
 
 
 
-No OS 
improvement and 
no effect has 
been seen in the 
case of 
melanoma spread 
to other internal 
organs 
 
 
 
-Sipuleucel-T is 
the first DCs-
based cancer 
vaccine for men 
with asymptomatic 
or minimally 
symptomatic 
metastatic 
castration-
resistant prostate 
cancer 
 
 
 
-Talimogene 
laherparepvec (T-
VEC) has been 
approved by the 
FDA for the 
treatment of  
surgically 
unresectable skin 
and lymph node 
lesions in patients 
with 
advanced 
melanoma 
 
 
 
 
 
86 
 
 
 
 
 
 
 
 
 
 
 
 
87 
 
 
ATC, anaplastic thyroid cancer; DCs, dendritic cells; DTC, differentiated thyroid cancer; FDA, Food 
and Drugd Administration; MTC, medullary thyroid cancer; NSCLC, non-small-cell lung cancer; OS, 
overall survival; PFS, progression-free survival; SCLC, small-cell lung cancer. 
 
